SCHEMBL16446568

SCHEMBL16446568

COc1ccc(-c2nc(C)c3c(I)cn(C(=O)OC(C)(C)C)c3n2)cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 5/20 0.39
▸ SMPD3 Q9NY59 2/20 0.39
▸ ALDH1A1 P00352 4/20 0.37
▸ RAB9A P51151 3/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ NFKB1 P19838 1/20 0.37
▸ NFKB2 Q00653 1/20 0.37
▸ RELA Q04206 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ MAPT P10636 3/20 0.37
▸ KDM4E B2RXH2 3/20 0.37
▸ LMNA P02545 2/20 0.37
▸ PIK3CA P42336 1/20 0.36
▸ PTGS1 P23219 2/20 0.36
▸ PTGS2 P35354 2/20 0.36
▸ GLA P06280 1/20 0.35
▸ MAPK1 P28482 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16446286 0.82 PDE4B (0.45) PDE4BSMPD3ALDH1A1RAB9ANPC1
SCHEMBL19118427 0.78 PDE4B (0.41) PDE4BSMPD3ALDH1A1RAB9ANPC1
SCHEMBL16446529 0.74 PDE4B (0.47) PDE4BSMPD3ALDH1A1RAB9ANPC1
SCHEMBL10104606 0.69 CFTR (0.36) PDE4B
SCHEMBL16446457 0.69 TRPA1 (0.42) ALDH1A1RAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL17784219 0.67 PDE4B (0.59) PDE4BPTGS1PTGS2
SCHEMBL16446564 0.66 PDE4B (0.64) PDE4BSMPD3ABHD6
SCHEMBL2991802 0.65 MTNR1A (0.35) PDE4BSMPD3L3MBTL1
SCHEMBL16447006 0.65 PDE4B (0.64) PDE4BRAB9ALMNAPIK3CAPTGS1
SCHEMBL16447005 0.65 PDE4B (0.64) PDE4BRAB9ALMNAPIK3CAPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030565-B1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS GRUENENTHAL GMBH (DE) 2017-07-19 — — EP disclosed
US-9688683-B2 Substituted condensed pyrimidine compounds Grünenthal GmbH (DE) 2017-06-27 — — US disclosed
EP-3030565-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-15 — — EP disclosed
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-02 — — US disclosed
WO-2015018534-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2015-02-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS PDE4A, PDE4B, TYMP PDE4B 2/4885SMPD3 235/4885ALDH1A1 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback